Home » What s the Fuss about OGS? Breast Cancer Protein Findings Provide Clues

What s the Fuss about OGS? Breast Cancer Protein Findings Provide Clues

Mar 03, 2003
Premium

Last week, Oxford GlycoSciences management spurned a takeover bid by UK biotech Celltech, signaling that the company’s merger with Cambridge Antibody Technology announced Jan. 23 is more likely to go forward.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Blame the Follicles

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Missed a Few

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

This Week in Cell

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

What's Popular?

In Proteomics & Protein Research

  1. Proteogenomic Approach Identifies Candidate Tumor-Specific Antigens for Immunotherapies

  2. Nanoparticle Enrichment Could Enhance Plasma Protein Biomarker Discovery

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.